Yourgene Health PLC Total Voting Rights (6581X)
May 01 2019 - 3:05AM
UK Regulatory
TIDMYGEN
RNS Number : 6581X
Yourgene Health PLC
01 May 2019
Yourgene Health plc
("Yourgene" or the "Company")
Total Voting Rights
Manchester, UK - 1 May 2019: Yourgene Health plc (AIM: YGEN),
the international molecular diagnostics group which commercialises
genetic products and services, announces that the Consideration
Shares have today been admitted to trading on AIM and total voting
rights are 598,999,688 after full completion of all aspects of the
Fundraise and the Acquisition in the announcement dated 17 April
2019.
The Company's issued share capital as at the date and time of
this announcement consist of 598,999,688 ordinary shares of 0.1
pence each ('Ordinary Shares'). There are no Ordinary Shares held
in treasury.
Accordingly, the total number of voting rights in Yourgene
Health plc at the date of this notice is 598,999,688.
The above figure of 598,999,688 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure and
Transparency Rules.
Capitalised terms used but not defined in this announcement have
the same meanings as defined in the Company's announcement released
on 17 April 2019, detailing the proposed acquisition by the Company
of Elucigene.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)20 7213
Liam Murray / James Caithie / Ludovico Lazzaretti 0880
Stifel Nicolaus Europe Limited (Broker) Tel: +44 (0)20 7710
Nicholas Moore / Matthew Blawat / Ben Maddison 7600
Vigo Communications (PR) Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0238
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions.
Yourgene Health's first commercialised products are NIPT for
Down's Syndrome and other genetic disorders, targeting a share of
an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but
accuracy challenges with traditional methods are driving the need
for NIPT and other DNA-based reproductive health testing solutions.
Our commercial footprint is already established in the UK, Europe,
the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene
Health is aiming to extend its genetic testing offering into
complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRWGUMCCUPBPGU
(END) Dow Jones Newswires
May 01, 2019 03:05 ET (07:05 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024